UBS initiated coverage with a ‘Buy’ rating and set a $1,250 price target, citing confidence in Lilly’s obesity execution.

Eli Lilly shares surged over 4.5% on analyst upgrades, acquisition rumors involving Ventyx Biosciences, and a new $1.3 ...

Eli Lilly briefly reached $1 trillion in market cap last year before retreating. The company has seen revenue soar in recent ...

Eli Lilly stock reached an all-time high of 1113.03 USD, marking a significant milestone for the pharmaceutical giant. This achievement reflects a robust 41.51% increase over the past year, ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of ...

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Ventyx Biosciences stock surged 62% after reports Eli Lilly is in talks to acquire the biotech firm for over $1B. Deal could ...

Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company’s portfolio of weight loss drugs, which has generated blockbuster revenue. Investors generally ...

Eli Lilly and Company’s LLY stock has risen 18% in a month, driven mainly by a stellar third-quarter performance. Also, earlier this month, President Trump announced deals with Lilly and rival Novo ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...